Superworth

Advanced Biomed ADVB

Medical - Diagnostics & Research, Healthcare
$2.08
−9.78%
Market cap
$3.4M
PE
n/m
not a meaningful number
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
0.1×
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
Q4 FY26 missing

Charts

Financials

Income statement for ADVB, by quarter
Income statementQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
R&D$169.2K$188.4K$313.5K$209.1K$181.7K+7%$212.4K+13%$220K−30%$234.2K+12%$236K+30%$186.3K−12%$243.2K+11%n/a
SG&A$271.1K$462.9K$431.9K$495.5K$338.3K+25%$67.7K−85%$347.5K−20%$611.4K+23%$287.9K−15%$210.3K+211%$276.6K−20%$4M+551%
Pre-tax income−$771.3K−$145.3K−$1.1M−$809.4K−$265.6K−66%−$579.5K+299%−$1.2M+13%$675.6K−$386.9K+46%$7M−$488.9K−59%−$12.5M
Net income−$771.3K−$145.3K−$1.1M−$809.4K−$265.6K−66%−$907.9K+525%−$1.4M+31%−$701.6K−13%−$386.9K+46%$6.9M−$488.9K−65%$695K
−$0.80−$0.20−$1.00−$0.80−$0.20−75%−$1.00+400%−$1.35+35%−$0.65−19%−$0.40+100%$6.20−$0.38−72%$0.44
1M1M1M1M1M+0%1M+0%1M+2%1.1M+8%1.1M+8%1.1M+8%1.3M+26%1.6M+45%

R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.

SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.

Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.

EPS, diluted: 5 periods, Q1 FY24 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY24 and Q1 FY25: share-days: the 6-month average less the second quarter's. Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Advanced Biomed's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ADVBAdvanced Biomed$3.4Mn/m3.0×n/mn/mn/m
OXBROXBRIDGE RE HOLDINGS$6.5M40.2×9.8×2.4×+40%4.7%
EDUCEducational Development$8.9M5.5×11.3×0.4×−32%8.6%
GTIMGood Times Restaurants$14M6.3×13.5×0.1×−6%1.7%
MDRRMedalist Diversified$17.9M2.9×3.0×1.9×−1%80.2%
VIPVulcan Infrastructure & Power$18.4M16.7×22.5×0.4×−14%1.0%
BCGBinah Capital$18.6M6.8×20.0×0.1×+8%2.2%
MXCMexco Energy$19.2M12.5×13.3×2.8×−9%23.3%
ATCHAtlasClear$20.6M13.6×16.7×1.0×+85%9.8%
CKXCKX Lands$21.9M7.5×32.5×31.5×−17%n/m
MSGMMotorsport Games$22.8M11.5×11.5×1.6×+79%16.2%
Peer median$18.5M9.5×13.4×1.3×−3%8.6%

More on Advanced Biomed

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .